Investing.comCodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:04:39时区推断·⟳ 抓取 19:11:22·⚡ 决策 08-04 22:57:03 +3h45m·84.0 天前
Nurix因赛诺菲启动STAT6降解剂1期临床获得1000万美元里程碑付款
本事件对Nurix（NRIX.US）方向为正面，但同一具体催化已在已处理消息库中于08-04 11:06 UTC和11:08 UTC完成研判。
📄 原文Investing.com↗ 原文
Nurix earns $10m milestone as Sanofi starts STAT6 degrader trial
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets BRISBANE, Calif. - Nurix Therapeutics Inc. (NA…
不做 Nurix Therapeutics（NRIX.US）
同一具体催化已在已处理消息库08-04 11:06 UTC和11:08 UTC命中并判定不做，本条为Investing.com重复转述，不再推卡或交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本事件对Nurix（NRIX.US）方向为正面，但同一具体催化已在已处理消息库中于08-04 11:06 UTC和11:08 UTC完成研判。
- 1000万美元里程碑付款和STAT6项目进入1期临床属于早期研发进展，不构成新的未处理交易卡片。
主要风险
- 重复转述不应再次推卡或重复延长交易窗口。
- 行情服务与内部KB本轮返回故障，因此未补充最新价格或更细业绩量级。
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,960 字
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
BRISBANE, Calif. - Nurix Therapeutics Inc. (NASDAQ:NRIX) announced today it received a $10 million milestone payment from Sanofi following the initiation of a Phase 1 clinical trial for SAR448272/NX-3911, an oral STAT6 degrader for type 2 inflammatory diseases.
The payment brings Nurix’s total receipts under its 2019 collaboration agreement with Sanofi to approximately $139 million. The company remains eligible to receive approximately $453 million in future development, regulatory and commercial milestone payments associated with the STAT6 program, plus potential royalties on product sales, according to a press release statement.
STAT6 is a transcription factor within the interleukin-4 and interleukin-13 signaling pathways that drive type 2 inflammation in diseases including atopic dermatitis and asthma. Sanofi is solely responsible for the ongoing clinical development of SAR448272.
Under the collaboration agreement executed in December 2019, Sanofi made an initial upfront payment of $55 million and subsequently paid $22 million to expand the collaboration scope. In June 2025, Sanofi exercised its exclusive license extension option for the STAT6 program and an undisclosed target, triggering two $15 million license extension payments.
Nurix retains an option to co-develop, co-promote, and share profits and losses for the STAT6 program equally in the United States following demonstration of clinical proof of concept.
The Brisbane, California-based company deployed its DEL-AI drug discovery platform to identify agents that utilize E3 ligases to induce the degradation of specified proteins under the collaboration. Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BRISBANE, Calif. - Nurix Therapeutics Inc. (NASDAQ:NRIX) announced today it received a $10 million milestone payment from Sanofi following the initiation of a Phase 1 clinical trial for SAR448272/NX-3911, an oral STAT6 degrader for type 2 inflammatory diseases.
The payment brings Nurix’s total receipts under its 2019 collaboration agreement with Sanofi to approximately $139 million. The company remains eligible to receive approximately $453 million in future development, regulatory and commercial milestone payments associated with the STAT6 program, plus potential royalties on product sales, according to a press release statement.
STAT6 is a transcription factor within the interleukin-4 and interleukin-13 signaling pathways that drive type 2 inflammation in diseases including atopic dermatitis and asthma. Sanofi is solely responsible for the ongoing clinical development of SAR448272.
Under the collaboration agreement executed in December 2019, Sanofi made an initial upfront payment of $55 million and subsequently paid $22 million to expand the collaboration scope. In June 2025, Sanofi exercised its exclusive license extension option for the STAT6 program and an undisclosed target, triggering two $15 million license extension payments.
Nurix retains an option to co-develop, co-promote, and share profits and losses for the STAT6 program equally in the United States following demonstration of clinical proof of concept.
The Brisbane, California-based company deployed its DEL-AI drug discovery platform to identify agents that utilize E3 ligases to induce the degradation of specified proteins under the collaboration. Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。